Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
Clinical trial NCT06411002 · COMPLETED
Trial details
- NCT number
- NCT06411002
- Sponsor
- Revance Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-08
- Primary completion
- 2024-12-12
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.